Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUTSTAND-2: HRS-7535 vs Dapagliflozin in Type 2 Diabetes
NCT06589765Phase 3Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Sep 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-7535 in type 2 diabetes mellitus (T2DM), sponsored by Shandong Suncadia Medicine Co., Ltd.. Started Sep 2024; status: completed.
02
Drugs
HRS-7535
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06589765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589765.